Literature DB >> 21378033

Targeting transforming growth factor βRII expression inhibits the activation of hepatic stellate cells and reduces collagen synthesis.

Rongquan Fu1, Jinguo Wu, Jiguang Ding, Jifang Sheng, Liang Hong, Qingfeng Sun, Hui Fang, Dairong Xiang.   

Abstract

Abnormal production of extracellular matrix (ECM) components significantly contributes to the development of liver fibrosis. This study aimed at examining the effects of short-hairpin RNA (shRNA)-mediated transient knockdown of transforming growth factor βRII (TGFβRII) expression on the proliferation and activation of hepatic stellate cells (HSCs) and synthesis of fibrogenic ECM components in HSC cells. Three different shRNA-expressing plasmids were constructed for the expression of shRNA-(a, b, c) targeting to the rat TGFβRII mRNA beginning at nucleotide position 339, 444 and 528 and they were transfected into a rat stellate cell line, HSC-T6 cells, respectively. The levels of TGFβRII, α-smooth muscle actin (α-SMA), and type I and III collagen expressions were characterized by reverse transcription polymerase chain reaction and Western blot assays. The concentrations of hyaluronic acid (HA) and type IV collagen in the supernatants of cultured cells were measured by enzyme-linked immunosorbent assay. Transfection with the TGFβRII-specific shRNAs resulted in varying levels of inhibition in the expression of TGFβRII in HSC-T6 cells, and transfection with the potent shRNA-c inhibited the expression of TGFβRII in a dose-dependent manner. Knockdown of TGFβRII expression significantly reduced the levels of α-SMA, type I, III and IV collagen, and HA expression in HSC-T6 cells (P < 0.01). In conclusion, our data indicated that knockdown of TGFβRII expression inhibited the activation of HSCs and the production of fibrogenic ECM components in HSC-T6 cells. Therefore, our findings support the notion that TGFβRII is an important factor of the pathogenic process of liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21378033     DOI: 10.1258/ebm.2010.010231

Source DB:  PubMed          Journal:  Exp Biol Med (Maywood)        ISSN: 1535-3699


  6 in total

1.  MicroRNAs in Liver Disease: Bench to Bedside.

Authors:  Nihar Shah; James E Nelson; Kris V Kowdley
Journal:  J Clin Exp Hepatol       Date:  2013-09-17

Review 2.  siRNA- and miRNA-based therapeutics for liver fibrosis.

Authors:  Zhen Zhao; Chien-Yu Lin; Kun Cheng
Journal:  Transl Res       Date:  2019-08-13       Impact factor: 7.012

Review 3.  Targeted TFO delivery to hepatic stellate cells.

Authors:  Ningning Yang; Saurabh Singh; Ram I Mahato
Journal:  J Control Release       Date:  2011-07-08       Impact factor: 9.776

Review 4.  Fibroblasts in fibrosis: novel roles and mediators.

Authors:  Ryan T Kendall; Carol A Feghali-Bostwick
Journal:  Front Pharmacol       Date:  2014-05-27       Impact factor: 5.810

5.  Beneficial effects of ascorbic acid to treat lung fibrosis induced by paraquat.

Authors:  Marcia Rodrigues da Silva; Adriana Schapochnik; Mayara Peres Leal; Janete Esteves; Cristina Bichels Hebeda; Silvana Sandri; Christiane Pavani; Anna Carolina Ratto Tempestini Horliana; Sandra H P Farsky; Adriana Lino-Dos-Santos-Franco
Journal:  PLoS One       Date:  2018-11-05       Impact factor: 3.240

6.  Cyclam-Modified Polyethyleneimine for Simultaneous TGFβ siRNA Delivery and CXCR4 Inhibition for the Treatment of CCl4-Induced Liver Fibrosis.

Authors:  Aftab Ullah; Gang Chen; Abid Hussain; Hanif Khan; Azar Abbas; Zhanwei Zhou; Muhammad Shafiq; Saleem Ahmad; Usman Ali; Muhammad Usman; Faisal Raza; Abrar Ahmed; Zijie Qiu; Maochao Zheng; Daojun Liu
Journal:  Int J Nanomedicine       Date:  2021-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.